Consolidated and Standalone Audited Financial Results of the Company for the quarter and year ended March 31, 2026, is attached.
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Agarwal's Health Care Limited delivered strong FY2026 results with Total Income surging 20.9% YoY to ₹2,125 Crores. Revenue from Operations grew 21.6% to ₹2,080 Crores, crossing the ₹2,000 crore milestone for the first time. EBITDA expanded 22.2% to ₹614 Crores with margins at 28.9%, while PAT grew 52.4% to ₹168 Crores. The company added 57 new facilities during the year, taking its network to 288 facilities across 10 countries, and performed 323,245 surgeries (up 14.5% YoY). Mature facilities showed particularly strong growth at 35.3%. The Board also approved reallocation of ₹14.88 Crores of unspent IPO proceeds from Issue Related Expenses to General Corporate Purposes. Auditors S.R. Batliboi & Associates LLP issued an unmodified opinion with no going concern or qualification flags.
The company demonstrates robust growth across all metrics with improving profitability. PAT growth of 52.4% significantly outpaces revenue growth, indicating operational leverage. The strong cash generation (operating cash flow of ₹519 Crores) and expansion of the network position the company well for continued growth. Clean audit opinion with no concerns supports financial reliability.